Animal Naming Test - a simple and accurate test for diagnosis of minimal hepatic encephalopathy and prediction of overt hepatic encephalopathy.
cirrhosis
hepatic encephalopathy
minimal hepatic encephalopathy
Journal
Clinical and experimental hepatology
ISSN: 2392-1099
Titre abrégé: Clin Exp Hepatol
Pays: Poland
ID NLM: 101703431
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
24
11
2019
accepted:
05
03
2020
entrez:
31
7
2020
pubmed:
31
7
2020
medline:
31
7
2020
Statut:
ppublish
Résumé
Minimal hepatic encephalopathy (MHE) is the mildest form in the spectrum of hepatic encepha-lopathy (HE). We compared the usefulness of the Psychometric Hepatic Encephalopathy Score (PHES) and Animal Naming Test (ANT) for the diagnosis of MHE and the prediction of the development of overt episodes of HE. 103 consecutive patients with liver cirrhosis without overt HE were subjected to PHES and ANT evaluation. The receiver-operating characteristic curve was used to determine the optimum cut-off of the ANT value for the diagnosis of MHE. Thirty-seven (35.9%) patients had MHE as assessed by altered PHES. ANT (< 14) was positive in 36 (34.95%) patients with MHE with a sensitivity of 89.19% and specificity of 95.7%, positive predictive value (PPV) of 91.67%, negative predictive value (NPV) of 94.03% and diagnostic accuracy of 93.20%. The area under the curve for diagnosis of MHE was 0.978 (95% CI: 0.954-1.0). MHE patients had significantly lower ANT as compared to non-MHE patients and controls (10.81 ±0.324 vs. 15.27 ±0.147 vs. 15.78 ±0.192, respectively, ANT is simple and accurate for the diagnosis of MHE and prediction of overt episodes of HE in patients with cirrhosis and correlates well with the Child-Pugh and MELD scores.
Identifiants
pubmed: 32728628
doi: 10.5114/ceh.2019.95105
pii: 40582
pmc: PMC7380476
doi:
Types de publication
Journal Article
Langues
eng
Pagination
116-124Informations de copyright
Copyright © 2020 Clinical and Experimental Hepatology.
Déclaration de conflit d'intérêts
The authors report no conflict of interest.
Références
Dig Dis Sci. 2010 Aug;55(8):2381-90
pubmed: 20508990
Hepatology. 2007 Apr;45(4):879-85
pubmed: 17393525
Hepatology. 2009 Oct;50(4):1175-83
pubmed: 19670416
Hepatology. 2013 Sep;58(3):1122-32
pubmed: 23389962
Am J Gastroenterol. 2018 Apr;113(4):529-538
pubmed: 29533396
Hepatobiliary Pancreat Dis Int. 2018 Feb;17(1):9-16
pubmed: 29428113
J Clin Exp Hepatol. 2012 Dec;2(4):306-14
pubmed: 25755452
Hepatology. 2007 Mar;45(3):549-59
pubmed: 17326150
J Hepatol. 2008 Sep;49(3):346-53
pubmed: 18602716
Hepatology. 2008 Feb;47(2):596-604
pubmed: 18000989
Metab Brain Dis. 2013 Jun;28(2):227-9
pubmed: 22993201
Hepatology. 2002 Feb;35(2):357-66
pubmed: 11826409
Hepatology. 2017 Jul;66(1):198-208
pubmed: 28271528
Liver. 2002 Jun;22(3):190-7
pubmed: 12100568
Metab Brain Dis. 2016 Dec;31(6):1463-1471
pubmed: 27461111
Hepatology. 2002 Mar;35(3):716-21
pubmed: 11870389
World J Gastroenterol. 2014 Nov 14;20(42):15756-62
pubmed: 25400460
Clin Liver Dis. 2015 Aug;19(3):461-72
pubmed: 26195201
J Clin Exp Hepatol. 2018 Jun;8(2):156-161
pubmed: 29892178
Hepatology. 2014 Aug;60(2):715-35
pubmed: 25042402
J Clin Exp Hepatol. 2015 Mar;5(Suppl 1):S42-8
pubmed: 26041957
J Gastroenterol Hepatol. 1995 Jan-Feb;10(1):14-23
pubmed: 7620102
J Clin Exp Hepatol. 2019 Jul-Aug;9(4):476-483
pubmed: 31516264
J Hepatol. 2001 May;34(5):768-73
pubmed: 11434627
Nat Clin Pract Gastroenterol Hepatol. 2007 Dec;4(12):677-85
pubmed: 18043677
Ann Gastroenterol. 2018 Mar-Apr;31(2):151-164
pubmed: 29507462
Aliment Pharmacol Ther. 2018 Aug;48(3):313-321
pubmed: 29863286
J Gastroenterol Hepatol. 2010 Jun;25(6):1029-41
pubmed: 20594216
Gastroenterology. 2008 Nov;135(5):1591-1600.e1
pubmed: 18723018